{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:06:38Z","timestamp":1793127998714,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"DOI":"10.1007\/s11904-026-00782-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:33:54Z","timestamp":1774424034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV?"],"prefix":"10.1007","volume":"23","author":[{"given":"Paula","family":"Debroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan E.","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"6","key":"782_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2019","unstructured":"Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2019;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999. PubMed PMID: 31606734; PubMed Central PMCID: PMC7486849.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"782_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","volume":"17","author":"SS Bailin","year":"2020","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV\/AIDS Rep. 2020;17(2):138\u201350. https:\/\/doi.org\/10.1007\/s11904-020-00483-5. PubMed PMID: 32072466; PubMed Central PMCID: PMC7719267.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"782_CR3","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3018","volume":"8","author":"L Bansi-Matharu","year":"2021","unstructured":"Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, G\u00fcnthard HF, De Wit S, et al. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021;8(11):e711\u201322. https:\/\/doi.org\/10.1016\/S2352-3018. (21)00163-6 PubMed PMID: 34555326.","journal-title":"Lancet HIV"},{"key":"782_CR4","doi-asserted-by":"publisher","unstructured":"Zhang L, Wu X, He Y, Song Y, Li B, Zhang Q, et al. Impact of different INSTIs on BMI among people living with HIV who newly started ART in Shenzhen, China: a real-world data analysis. Clin Infect Dis. 2025;ciaf466. https:\/\/doi.org\/10.1093\/cid\/ciaf466. PubMed PMID: 40834233.","DOI":"10.1093\/cid\/ciaf466"},{"key":"782_CR5","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new. Accessed December 2025."},{"issue":"1","key":"782_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/aid.2015.0147","volume":"32","author":"JR Koethe","year":"2016","unstructured":"Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016;32(1):50\u20138. https:\/\/doi.org\/10.1089\/aid.2015.0147. PubMed PMID: 26352511; PubMed Central PMCID: PMC4692122.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"782_CR7","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","volume":"71","author":"J Gorwood","year":"2020","unstructured":"Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human\/Simian Adipose Tissue and Human Adipocytes. Clin Infect Dis. 2020;71(10):e549\u201360. https:\/\/doi.org\/10.1093\/cid\/ciaa259.","journal-title":"Clin Infect Dis"},{"key":"782_CR8","doi-asserted-by":"publisher","unstructured":"Souza SJ, Luzia LA, Santos SS, Rond\u00f3 PHC. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras (1992). 2013;59(2):186\u201398. https:\/\/doi.org\/10.1016\/j.ramb.2012.11.003","DOI":"10.1016\/j.ramb.2012.11.003"},{"key":"782_CR9","unstructured":"Jung I, Jin S, Tu-Sekine B, Anokye-Danso F, Brown TT, Kim S. A loss of ER\u03b1 attenuates DTG-mediated disruption of thermogenesis in brown adipocytes [abstract 147]. In. 2023."},{"issue":"7","key":"782_CR10","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1016\/S2352-3018(","volume":"8","author":"O Ogbuagu","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8(7):e397\u2013407. https:\/\/doi.org\/10.1016\/S2352-3018(. 21)00071-0 PubMed PMID: 34197772; PubMed Central PMCID: PMC12492902.","journal-title":"Lancet HIV"},{"issue":"1","key":"782_CR11","doi-asserted-by":"publisher","first-page":"2339576","DOI":"10.1080\/25787489.2024.2339576","volume":"25","author":"AE Kousari","year":"2024","unstructured":"Kousari AE, Wilson MP, Hawkins KL, Bandali MM, Henao-Mart\u00ednez AF, Gardner EM, et al. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV. HIV Res Clin Pract. 2024;25(1):2339576. PubMed PMID: 38831550; PubMed Central PMCID: PMC12008775.","journal-title":"HIV Res Clin Pract"},{"issue":"4","key":"782_CR12","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24(4):e25702. https:\/\/doi.org\/10.1002\/jia2. 25702 PubMed PMID: 33838004; PubMed Central PMCID: PMC8035674.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"782_CR13","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab","volume":"73","author":"KM Erlandson","year":"2021","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis. 2021;73(8):1440\u201351. https:\/\/doi.org\/10.1093\/cid\/ciab. 444 PubMed PMID: 33987636; PubMed Central PMCID: PMC12097995.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"782_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","volume":"37","author":"A Perna","year":"2023","unstructured":"Perna A, Carleo MA, Mascolo S, Guida A, Contieri M, Sellitto C, et al. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model. AIDS. 2023;37(4):561\u201370. .0000000000003455 PubMed PMID: 36504092; PubMed Central PMCID: PMC9994803.","journal-title":"AIDS"},{"issue":"4","key":"782_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/infdis\/jis720","volume":"207","author":"GA McComsey","year":"2013","unstructured":"McComsey GA, Daar ES, O\u2019Riordan M, Collier AC, Kosmiski L, Santana JL, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013;207(4):604\u201311. https:\/\/doi.org\/10.1093\/infdis\/jis720. PubMed PMID: 23204164; PubMed Central PMCID: PMC3549598.","journal-title":"J Infect Dis"},{"issue":"5","key":"782_CR16","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211\u201320. https:\/\/doi.org\/10.1016\/S2352-3018. (18)30021-3 PubMed PMID: 29592840.","journal-title":"Lancet HIV"},{"issue":"4","key":"782_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, et al. Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus\u20131 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68(4):535\u201344. https:\/\/doi.org\/10.1093\/cid\/ciy540.","journal-title":"Clin Infect Dis"},{"issue":"4S3","key":"782_CR18","doi-asserted-by":"publisher","first-page":"19532","DOI":"10.7448\/IAS.17.4.19532","volume":"17","author":"JM Gatell","year":"2014","unstructured":"Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Keikawus A, Hoffmann C, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF\/FTC in ART-naive HIV-positive patients. J Int AIDS Soc. 2014;17(4S3):19532. https:\/\/doi.org\/10.7448\/IAS.17.4.19532.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"782_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","volume":"87","author":"P Kumar","year":"2021","unstructured":"Kumar P, Johnson M, Molina JM, Rizzardini G, Cahn P, Bickel M, et al. Brief Report: Switching to DOR\/3TC\/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2021;87(2):801\u20135. .0000000000002642 PubMed PMID: 33633036; PubMed Central PMCID: PMC8126485.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"782_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jac\/dkad","volume":"79","author":"KM Erlandson","year":"2023","unstructured":"Erlandson KM, Mohaweche R, Morrow M, Mawhinney S, Khuu V, Boyd M, et al. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV. J Antimicrob Chemother. 2023;79(1):179\u201385. https:\/\/doi.org\/10.1093\/jac\/dkad. 363 PubMed PMID: 38000089; PubMed Central PMCID: PMC10761240.","journal-title":"J Antimicrob Chemother"},{"key":"782_CR21","doi-asserted-by":"publisher","unstructured":"Garofoli N, Flandre P, Vincensini JP, Richier Q, Couture P, Lacombe K, et al. Impact on weight of a Doravirine switch in people living with HIV. HIV Med. 2025 Sep;30. https:\/\/doi.org\/10.1111\/hiv.70123. PubMed PMID: 41024657.","DOI":"10.1111\/hiv.70123"},{"issue":"1","key":"782_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/hiv.13711","volume":"26","author":"J Woods","year":"2025","unstructured":"Woods J, Sokhela S, Akpomiemie G, Bosch B, M\u00f6ller K, Bhaskar E, et al. DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir\u2010 or efavirenz\u2010 to doravirine\u2010based first\u2010line antiretroviral therapy. HIV Med. 2025;26(1):81\u201396. https:\/\/doi.org\/10.1111\/hiv.13711","journal-title":"HIV Med"},{"key":"782_CR23","unstructured":"Koethe JR, Lake JE, Kantor A, Smeaton laura, Erlandson KM, Moran L. A Switch to Doravirine Does Not Change Weight Trajectory at 48 Weeks Among Obese Individuals with HIV on Integrase Inhibitors and Tenofovir Alafenamide: Results of ACTG Study A5391. In. Rwanda; 2025."},{"issue":"1","key":"782_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12981-025-00761-5","volume":"22","author":"K Mounzer","year":"2025","unstructured":"Mounzer K, Brunet L, Sension M, Hsu RK, Osterman MD, Fusco JS, et al. Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study. AIDS Res Ther. 2025;22(1):64. https:\/\/doi.org\/10.1186\/s12981-025-00761-5. PubMed PMID: 40544263; PubMed Central PMCID: PMC12182698.","journal-title":"AIDS Res Ther"},{"issue":"8","key":"782_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/hiv.13644","volume":"25","author":"L Calza","year":"2024","unstructured":"Calza L, Giglia M, Colangeli V, Bon I, Vitale S, Viale P. Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine\/tenofovir disoproxil fumarate\/lamivudine in people with significant weight gain. HIV Med. 2024;25(8):919\u201326. https:\/\/doi.org\/10.1111\/hiv.13644.","journal-title":"HIV Med"},{"issue":"4","key":"782_CR26","doi-asserted-by":"publisher","first-page":"e0081524","DOI":"10.1128\/aac.00815-24","volume":"69","author":"A Lazzaro","year":"2025","unstructured":"Lazzaro A, Recchia GE, Alessi F, Santinelli L, Battistini L, Morcos J, et al. Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort. Antimicrob Agents Chemother. 2025;69(4):e0081524. https:\/\/doi.org\/10.1128\/aac.00815-24. PubMed PMID: 39964162; PubMed Central PMCID: PMC11963538.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"782_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/03007995.2020.1775074","volume":"36","author":"W Chow","year":"2020","unstructured":"Chow W, Donga P, C\u00f4t\u00e9-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr Med Res Opin. 2020;36(8):1313\u201323. .1775074 PubMed PMID: 32459155.","journal-title":"Curr Med Res Opin"},{"key":"782_CR28","doi-asserted-by":"publisher","unstructured":"Donga P, Emond B, Shah A, Bookhart BK, Anderson D, Vermette-Laforme M et al. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors. J Comp Eff Res 12(1):e220147. https:\/\/doi.org\/10.2217\/cer-2022-0147 PubMed PMID: 36445208; PubMed Central PMCID: PMC10288953.","DOI":"10.2217\/cer-2022-0147"},{"issue":"3","key":"782_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/cid\/ciae449","volume":"80","author":"D Anderson","year":"2025","unstructured":"Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, et al. A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor\u2013Based Regimen Switch Strategy to Manage Integrase Inhibitor\u2013Related Weight Gain. Clin Infect Dis. 2025;80(3):602\u201312. https:\/\/doi.org\/10.1093\/cid\/ciae449.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"782_CR30","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666\u201376. https:\/\/doi.org\/10.1016\/S2352-3018(. 20)30241-1 PubMed PMID: 33010240.","journal-title":"Lancet HIV"},{"issue":"8","key":"782_CR31","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/cid\/ciac949","volume":"76","author":"B Bosch","year":"2023","unstructured":"Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, et al. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide\/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)\/FTC\u2009+\u2009DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG. Clin Infect Dis. 2023;76(8):1492\u20135. https:\/\/doi.org\/10.1093\/cid\/ciac949.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"782_CR32","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/cid\/ciae","volume":"79","author":"J Damas","year":"2024","unstructured":"Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr PE, et al. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV. Clin Infect Dis. 2024;79(4):990\u20138. https:\/\/doi.org\/10.1093\/cid\/ciae. 189 PubMed PMID: 38606792; PubMed Central PMCID: PMC11478808.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"782_CR33","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and Safety of Switching to Dolutegravir\/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide\u2013Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71(8):1920\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz1243.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"782_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac. 130 PubMed PMID: 35235656; PubMed Central PMCID: PMC10021070.","journal-title":"Clin Infect Dis"},{"key":"782_CR35","doi-asserted-by":"publisher","unstructured":"Horberg M, Thompson M, Agwu A, Colasanti J, Haddad M, Jain M, et al. Primary Care Guidance for Providers Who Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024;ciae479. https:\/\/doi.org\/10.1093\/cid\/ciae479.","DOI":"10.1093\/cid\/ciae479"},{"issue":"1","key":"782_CR36","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab","volume":"9","author":"PWG Mallon","year":"2021","unstructured":"Mallon PWG, Brunet L, Fusco JS, Prajapati G, Beyer A, Fusco GP, et al. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infect Dis. 2021;9(1):ofab621. https:\/\/doi.org\/10.1093\/ofid\/ofab. 621 PubMed PMID: 35028335; PubMed Central PMCID: PMC8753026.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"782_CR37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3851\/IMP1518","volume":"15","author":"PA Randell","year":"2010","unstructured":"Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther. 2010;15(2):227\u201333. doi:10.3851\/IMP1518 PubMed PMID: 20386078.","journal-title":"Antivir Ther"},{"issue":"11","key":"782_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A Pilot Study to Determine the Impact on Dyslipidemia of Adding Tenofovir to Stable Background Antiretroviral Therapy: ACTG 5206. AIDS. 2010;24(11):1781\u20134. https:\/\/doi.org\/10.1097\/QAD.0b013e32833ad8b4. PubMed PMID: 20495438; PubMed Central PMCID: PMC2913151.","journal-title":"AIDS"},{"issue":"6","key":"782_CR39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3851\/IMP2305","volume":"17","author":"G Behrens","year":"2012","unstructured":"Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, et al. Switching to tenofovir\/emtricitabine from abacavir\/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17(6):1011\u201320. doi:10.3851\/IMP2305 PubMed PMID: 22910324.","journal-title":"Antivir Ther"},{"issue":"10","key":"782_CR40","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","volume":"36","author":"KJ Kauppinen","year":"2022","unstructured":"Kauppinen KJ, Aho I, Sutinen J. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. AIDS. 2022;36(10):1337\u201344. 10. 1097\/QAD.0000000000003245 PubMed PMID: 35727143.","journal-title":"AIDS"},{"issue":"1","key":"782_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1186\/s12879-021-06479-9","volume":"21","author":"PE Plum","year":"2021","unstructured":"Plum PE, Maes N, Sauvage AS, Frippiat F, Meuris C, Uurlings F, et al. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. BMC Infect Dis. 2021;21(1):910. https:\/\/doi.org\/10.1186\/s12879-021-06479-9. PubMed PMID: 34488664; PubMed Central PMCID: PMC8420041.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"782_CR42","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","volume":"35","author":"K McCann","year":"2021","unstructured":"McCann K, Shah S, Hindley L, Hill A, Qavi A, Simmons B, et al. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021;35(10):1657\u201365. 10. 1097\/QAD.0000000000002930 PubMed PMID: 33927086.","journal-title":"AIDS"},{"issue":"1","key":"782_CR43","doi-asserted-by":"publisher","first-page":"ofz472","DOI":"10.1093\/ofid\/ofz472","volume":"7","author":"GD Huhn","year":"2020","unstructured":"Huhn GD, Shamblaw DJ, Baril JG, Hsue PY, Mills BL, Nguyen-Cleary T, et al. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate. Open Forum Infect Dis. 2020;7(1):ofz472. https:\/\/doi.org\/10.1093\/ofid\/ofz472. PubMed PMID: 31950070; PubMed Central PMCID: PMC6954396.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"782_CR44","doi-asserted-by":"publisher","first-page":"ofaf177","DOI":"10.1093\/ofid\/ofaf177","volume":"12","author":"E Davies Smith","year":"2025","unstructured":"Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, et al. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025;12(4):ofaf177. https:\/\/doi.org\/10.1093\/ofid\/ofaf177. PubMed PMID: 40207047; PubMed Central PMCID: PMC11979587.","journal-title":"Open Forum Infect Dis"},{"key":"782_CR45","unstructured":"Ryan P, Blanco J, Masia M. Non-inferior efficacy and less weight gain when switching to DTG\/3TC than when switching to BIC\/FTC\/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial. Presented at the 25th International AIDS conference, Germany. 2024."},{"issue":"4","key":"782_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/QAI.0000000000003584","volume":"98","author":"DHS Tan","year":"2025","unstructured":"Tan DHS, Antinori A, Eu B, Galindo Puerto MJ, Kinder C, Sweet D, et al. Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir\/Emtricitabine\/Tenofovir Alafenamide. J Acquir Immune Defic Syndr. 2025;98(4):401\u20139. .0000000000003584 PubMed PMID: 39676239; PubMed Central PMCID: PMC11841724.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"782_CR47","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/QAD.0000000000003654","volume":"37","author":"ML Verburgh","year":"2023","unstructured":"Verburgh ML, Wit FWNM, Boyd A, Reiss P, Van der Valk M, on behalf of the ATHENA national observational cohort. No evidence of rapid reversibility of tenofovir alafenamide and\/or integrase strand transfer inhibitor-associated weight gain. AIDS. 2023;37(12):1843\u201350. .0000000000003654 PubMed PMID: 37433218; PubMed Central PMCID: PMC10481918.","journal-title":"AIDS"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00782-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00782-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:33:59Z","timestamp":1774424039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00782-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00782-3","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"JEL has worked as consultant for Gilead Sciences and ViiV health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10"}}